MedTrace Logo

Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds

NCT04346667 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2021-03-10

No results posted yet for this study

Summary

To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.

Conditions

Interventions

DRUG

Hydroxychloroquine Sulfate Regular dose

Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

DRUG

Hydroxychloroquine Sulfate Loading Dose

Hydroxychloroquine administered as a loading dose only

DRUG

Chloroquine

Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

DRUG

Placebo

Standard of Care plus placebo

Sponsors & Collaborators

  • Mayo Hospital Lahore

    collaborator OTHER

  • Services Institute of Medical Sciences, Pakistan

    collaborator OTHER_GOV

  • Pakistan Kidney and Liver Institute

    collaborator UNKNOWN

  • Forman Christian College, Pakistan

    collaborator OTHER

  • Harvard School of Public Health (HSPH)

    collaborator OTHER

  • Government of Punjab, Specialized Healthcare and Medical Education Department

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-14
Primary Completion
2020-08-23
Completion
2020-08-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04346667 on ClinicalTrials.gov